E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases

Malignant melanoma (MM) exhibits a high propensity for central nervous system dissemination with ~50% of metastatic MM patients developing brain metastases (BM). Targeted therapies and immune checkpoint inhibitors have improved overall survival for MM patients with BM. However, responses are usually...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Invest New Drugs
Huvudupphovsmän: Babiker, Hani M., Byron, Sara A., Hendricks, William P. D., Elmquist, William F., Gampa, Gautham, Vondrak, Jessica, Aldrich, Jessica, Cuyugan, Lori, Adkins, Jonathan, De Luca, Valerie, Tibes, Raoul, Borad, Mitesh J., Marceau, Katie, Myers, Thomas J., Paradiso, Linda J., Liang, Winnie S., Korn, Ronald L., Cridebring, Derek, Von Hoff, Daniel D., Carpten, John D., Craig, David W., Trent, Jeffrey M., Gordon, Michael S.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2018
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7519637/
https://ncbi.nlm.nih.gov/pubmed/30264293
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-018-0668-8
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk